Natera's Revenue True-Ups Fall To $32.3 Million As Its CEO Resigns

The third-quarter filing swaps the AI and billing-efficiency story for collections estimates catching up with cash, alongside a CEO change.

Share
Natera's Revenue True-Ups Fall To $32.3 Million As Its CEO Resigns

Natera, which runs blood-based genetic tests in oncology, women's health and organ health, booked $32.3 million of extra revenue in the third quarter from earlier tests whose cash came in above estimates, down from $55.1 million a year earlier. The 10-Q, filed Thursday, also discloses that CEO Steve Chapman resigned on November 4, and it explains the shrinking cushion differently than the last quarterly report did.

A smaller cushion, a different explanation

Natera estimates what insurers will eventually pay for a test, then books any cash collected above that estimate as a "change in estimate." The figure fell from $52.3 million in the second quarter, when the company credited its work on revenue cycle operations, automation and artificial intelligence, plus stronger reimbursement.

The third-quarter filing drops that language. It says instead that accumulated collection experience has made initial estimates of variable consideration track later cash collections more closely.

For the first nine months, changes in estimate totaled $145.6 million against $134.7 million a year earlier. Per share, the third-quarter change cut the loss by $0.22, versus $0.40 a year earlier, and the quarter's reported net loss was $0.42 per share.

Growth still outran the cushion

Total revenue rose 34.1% to $794.0 million, according to the company's earnings release, and net loss narrowed to $59.9 million from $87.5 million. The company raised 2026 revenue guidance to $3.005 billion to $3.035 billion, from $2.850 billion to $2.910 billion.

The filing shows accounts receivable up $174.8 million over nine months. Natera says cash generally arrives over about six to nine months after results are delivered. Its market value was $56.4 billion in the original report's pricing.

Leadership change

Chapman steps down as CEO, president and director effective November 5, staying on as an advisor. The filing says no disagreement over operations, policies or practices prompted the exit. His package: a $1,000,000 transition payment, a 2026 bonus with a $1,500,000 target, and consulting pay of $500 an hour for up to eight hours monthly.

Solomon Moshkevich, 44, takes over as CEO. He joined Natera in 2011 and most recently led clinical diagnostics as president. His contract provides a $900,000 base salary, a bonus target of 110% of salary and a 2027 equity award with a $10,500,000 target value.

On November 2, Natera also bought one of its strategic partners for up to $30.0 million, including up to $5.0 million in milestones.

Natera's 10-K for fiscal 2026 will include the Moshkevich and Chapman agreements as exhibits.

Sources

More on Natera

All Natera (NTRA) coverage →